MaxCyte, Inc. (NASDAQ:MXCT) Short Interest Up 55.1% in January
MaxCyte, Inc. (NASDAQ:MXCT) experienced a significant 55.1% increase in short interest in January, reaching 3,881,689 shares, which accounts for 3.8% of the stock's shares. The company, currently trading near its 12-month low of $0.68, has a market capitalization of approximately $76.8 million and is operating at a loss, with recent earnings and revenue missing analyst estimates. Analysts provide mixed ratings, with an average "Hold" and a price target of $7.00, while institutional investors hold about 68.8% of the shares.
Capricorn Fund Managers Ltd Acquires 8,200,000 Shares in MaxCyte Inc
Capricorn Fund Managers Ltd acquired 8,200,000 shares of MaxCyte Inc. on January 30, 2026, making it a new, significant holding in their portfolio and reflecting a strategic move in the healthcare sector. Despite MaxCyte Inc.'s current financial challenges, including operating at a loss and a low GF Score, the investment by Capricorn Fund Managers suggests confidence in the company's long-term potential. However, investors are advised to exercise caution and conduct thorough due diligence given MaxCyte's current low profitability and growth ranks.
MaxCyte, Inc. (NASDAQ:MXCT) Given Average Recommendation of "Hold" by Brokerages
MaxCyte, Inc. (NASDAQ:MXCT) has received a consensus "Hold" rating from five research firms, with an average 12-month price target of $7.00. The company recently missed earnings and revenue estimates, reporting a negative net margin and a current stock price of approximately $0.87. Institutional investors have increased their holdings in MaxCyte, despite the recent financial performance.
MaxCyte (NASDAQ:MXCT) Upgraded to Hold at Wall Street Zen
Wall Street Zen has upgraded MaxCyte (NASDAQ:MXCT) from "sell" to "hold," though Weiss Ratings still maintains a "sell (e+)." Despite a consensus "Hold" rating and a $7.00 price target from analysts, MaxCyte recently missed EPS and revenue estimates, trading near penny-stock levels with a market capitalization of approximately $86.2 million. Institutional ownership stands at about 68.8%, with some firms initiating small stakes despite the less-than-favorable financials.
MaxCyte (NASDAQ:MXCT) Stock Price Down 4.2% - Here's Why
MaxCyte (NASDAQ:MXCT) shares experienced a 4.2% drop, trading at $0.8691 on increased volume after closing at $0.9068. This decline follows the company's miss on quarterly earnings, reporting an EPS of ($0.12) against an expected ($0.11) and revenue of $6.41 million versus a $8.37 million consensus. Analysts' consensus rating for MaxCyte is "Hold" with an average target price of $7.00, though some, like Weiss Ratings and Wall Street Zen, have recently downgraded the stock to "Sell."
MaxCyte team building boosts morale at sales meeting
MaxCyte, a cell engineering company, recently conducted a team-building exercise at Dave & Buster's during its General Sales Meeting to boost staff morale and energize them for the upcoming year. This event, which included a scavenger hunt won by the Red Team, highlights MaxCyte's dedication to both scientific advancement and fostering a positive work environment. The company plans to leverage this positive momentum as it continues its focus on growth in cell engineering and gene editing for 2026.
MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Financial Results
MaxCyte, Inc. (Nasdaq: MXCT; LSE: MXCT) has released preliminary unaudited financial results for the fourth quarter and full year ended December 31, 2025. The company expects core revenue for the fourth quarter to be between $6.6 million and $6.7 million, with full-year core revenue projected between $29.5 million and $29.6 million. Despite a challenging year, MaxCyte achieved its guidance for core revenue and anticipates returning to revenue growth in the second half of 2026, supported by substantial cash reserves and a leaner organizational structure.
MaxCyte® acquires SeQure Dx to broaden cell engineering offerings with on-target and off-target editing assessments
MaxCyte has acquired SeQure Dx to enhance its cell engineering offerings by integrating advanced on-target and off-target editing assessment capabilities. This acquisition aims to improve the precision and safety of gene-editing applications within MaxCyte's technology platform.
MaxCyte (NASDAQ:MXCT) Stock Rating Lowered by Wall Street Zen
Wall Street Zen has downgraded MaxCyte (NASDAQ:MXCT) from "hold" to "sell," with Weiss Ratings also reaffirming a "sell (e+)" rating. Despite a consensus "Hold" rating and an average target price of $7.00, the company reported weak quarterly results, missing EPS and revenue estimates, and shows negative profitability. MaxCyte's shares are trading near a one-year low, and institutional investors hold a significant portion of the stock.
MaxCyte eyes growth in cell engineering for 2026
MaxCyte, a leader in cell engineering and gene editing, has announced its commitment to continued growth and development in 2026, focusing on innovation. The company aims to build on past successes and advance its technology, reaffirming its strategic priority to enhance capabilities in both cell engineering and gene editing. This strategy aligns with the increasing demand for cutting-edge solutions in the healthcare and biotechnology sectors.
MaxCyte advances GMP process with KSQ partnership
MaxCyte has significantly advanced its collaboration with KSQ Therapeutics by progressing a GMP-ready process, leading to the clearance of an Investigational New Drug (IND) application for KSQ-001EX. This partnership addresses scalability and TIL variability challenges in genetic editing and therapeutic development. The initiative aligns with MaxCyte's strategy to enhance cell therapy development, leveraging its ExPERT system for CAR T cell manufacturing optimization.
MaxCyte, Inc. (NASDAQ:MXCT) Given Consensus Rating of "Hold" by Brokerages
Five analysts have assigned MaxCyte, Inc. (NASDAQ:MXCT) a consensus "Hold" rating, with an average 12-month price target of $7.00. Despite missing recent quarterly earnings and revenue estimates, institutional investors have increased their positions in the company, signaling growing interest. MaxCyte shares currently trade around $1.47, reflecting a market capitalization of $156.8 million.
Mirabella Financial Services LLP Has $14.39 Million Stock Position in MaxCyte, Inc. $MXCT
Mirabella Financial Services LLP significantly increased its stake in MaxCyte, Inc. (NASDAQ:MXCT) by 78.4% in the second quarter, now holding 6,600,000 shares valued at approximately $14.39 million. This makes MaxCyte the 14th largest holding for Mirabella, representing 1.5% of its portfolio. Other institutional investors like Mudita Advisors, Gagnon Securities, Charles Schwab, and HSBC Holdings have also adjusted their positions, indicating notable institutional interest despite MaxCyte missing recent EPS and revenue estimates.
Cellares Appoints Former MaxCyte Commercial Chief Ali Soleymannezhad as Chief Commercial Officer to Lead Global IDMO Expansion, Catalyze Next Wave of Partnerships, Prepare for IPO
Cellares has appointed Ali Soleymannezhad, former Chief Commercial Officer at MaxCyte, as its new Chief Commercial Officer. He will lead the company's global commercial strategy and expansion of its IDMO Smart Factories across the US, Europe, and Japan, in preparation for a future IPO. Soleymannezhad brings over two decades of commercialization experience in cell therapy, aiming to secure long-term partnerships and address critical unmet manufacturing needs in the cell therapy industry.
Cellares Appoints Former MaxCyte Commercial Chief Ali Soleymannezhad as Chief Commercial Officer to Lead Global IDMO Expansion, Catalyze Next Wave of Partnerships, Prepare for IPO
Cellares has appointed Ali Soleymannezhad, former MaxCyte Commercial Chief, as its new Chief Commercial Officer. This strategic hire is intended to drive global IDMO expansion, foster new partnerships, and prepare the company for a future IPO. Soleymannezhad will lead efforts to secure long-term, multi-program partnerships as Cellares deploys its IDMO Smart Factories network to address manufacturing capacity and cost-efficiency barriers in cell therapy.
MaxCyte, Inc. (NASDAQ:MXCT) Receives Average Rating of "Hold" from Analysts
MaxCyte, Inc. (NASDAQ:MXCT) has received an average "Hold" rating from five research firms, with an average 12-month price target of $7.00. The company recently missed Q3 earnings and revenue estimates and exhibits negative net margin and return on equity. Institutional ownership is high at 68.81%, with shares trading around $1.67.
MaxCyte (NASDAQ: MXCT) begins CFO succession search, transition in first half 2026
MaxCyte (NASDAQ: MXCT) announced that CFO Douglas Swirsky will transition from his role in the first half of 2026. The company has initiated a structured search for his successor, and Mr. Swirsky will remain CFO until a successor is appointed and then continue in an advisory capacity. This planned transition is not expected to impact operations, financial reporting, or strategic priorities.
MaxCyte Misses Revenue Target But Stays Flush With Cash
MaxCyte missed its third-quarter revenue target, posting $6.8 million against an $8.36 million analyst expectation, due to sluggish demand in its core business. However, strong liquidity with $158 million in cash and investments, along with growth in Strategic Partnership License (SPL) related revenue, helped stabilize investor sentiment. All five analyst ratings remain a 'buy', with a consensus price target 72% above the current share price, underscoring the positive long-term outlook driven by strategic partnerships.
Recent Advancements in Cell Based Therapy
This article discusses the recent advancements in cell-based therapy, focusing on how genetic engineering and electroporation, particularly MaxCyte's Flow Electroporation technology, have revolutionized the field. James Brady from MaxCyte, Inc. explains how these techniques overcome traditional challenges in cell therapy development, enabling more efficient and scalable delivery of genetic payloads for therapeutic applications like CAR T cell development. The discussion highlights the benefits of electroporation in terms of versatility, scalability, and enhanced therapeutic efficacy compared to other transfection methods.
MaxCyte Signs Strategic Platform License with Moonlight Bio | MXCT Stock News
MaxCyte (Nasdaq: MXCT) has signed a Strategic Platform License (SPL) agreement with Moonlight Bio to advance T cell therapies for solid tumors. Under the agreement, Moonlight Bio gains non-exclusive rights to MaxCyte's Flow Electroporation® technology and ExPERT™ platform, and MaxCyte will receive annual licensing fees and program-related revenue. This partnership aims to support the scalable development and manufacturing of next-generation T cell therapies.
MaxCyte Signs Platform License Agreement With Adicet Bio
MaxCyte has signed a strategic platform license agreement with Adicet Bio, granting Adicet non-exclusive rights to MaxCyte's Flow Electroporation® technology and ExPERT™ platform for cell therapy development. This collaboration supports Adicet Bio's efforts in developing allogeneic gamma delta T cell therapies for cancer and autoimmune diseases, using non-viral gene editing and a robust expansion platform. MaxCyte will receive licensing fees and program-related revenue from the agreement.
MaxCyte signs platform license agreement with Adicet Bio for Gamma Delta T cell therapies
MaxCyte has signed a strategic platform license agreement with Adicet Bio, granting Adicet non-exclusive rights to use MaxCyte’s Flow Electroporation technology and ExPERT platform for gamma delta T cell therapy development. This collaboration aims to advance Adicet's gene-edited, allogeneic gamma delta T cell therapies for cancer and autoimmune diseases. MaxCyte will receive platform licensing fees and program-related revenue from the agreement.
PHC announces exclusive distribution of MaxCyte ExPERT platform in Japan
PHC Corporation's Biomedical Division (PHCbi) has secured an exclusive agreement with MaxCyte, Inc. to distribute the MaxCyte ExPERT platform in Japan. This partnership will provide researchers and manufacturers in Japan with access to MaxCyte's clinically proven, non-viral cell engineering technology, including various ExPERT instruments and related consumables. The agreement aims to advance next-generation cell therapeutics by enabling scalable and efficient cell engineering.
Moving Gene Editing Advances Into the Clinic
This article highlights how advances in base editing technology, specifically adenine base editing, offer a promising solution for treating sickle cell disease and other genetic blood disorders. Andrew Mancini of MaxCyte discusses a study demonstrating that editing the mutation responsible for sickle cell disease using ABE8e can eliminate cell sickling. The precise nature of base editing, combined with tools like MaxCyte's electroporation platform, is accelerating the translation of gene therapies from research to clinical application.
MaxCyte stockholders approve AIM delisting, company to trade only on Nasdaq
MaxCyte, Inc. (Nasdaq:MXCT; LSE:MXCT) shareholders have approved the delisting of the company's shares from the London AIM market, effective June 26, 2025. Following this, MaxCyte will trade exclusively on the Nasdaq Global Select Market. The company's CEO, Maher Masoud, thanked shareholders for their support since the 2016 AIM listing, noting its role in advancing cell and gene therapies.
Building the Future of Cell Therapies: Insights From Dr. Andrew Mancini
Dr. Andrew Mancini from MaxCyte discusses the significant evolution of engineered ex vivo cell therapies since 2017. He describes a shift from simple autologous T-cell therapies to more complex, diverse approaches involving NK cells and IPSCs, non-viral engineering, and a growing emphasis on allogeneic and transient therapies. Mancini anticipates continued complexity and highlights strategies for developers to navigate risks and maximize success in this rapidly expanding field.
MaxCyte Inc expected to post a loss of 11 cents a share - Earnings Preview
MaxCyte Inc is forecasted to report a loss of 11 cents per share for the period ending March 31, 2025, with an expected 20.2% decrease in revenue to $9.055 million. The average analyst rating is a "strong buy" with a median 12-month price target of $7.00, significantly above its last closing price of $2.82.
MaxCyte, Inc. (LON:MXCT) is largely controlled by institutional shareholders who own 65% of the company
Institutional shareholders control 65% of MaxCyte, Inc. (LON:MXCT), making the stock price sensitive to their trading actions. The top 12 shareholders collectively own 50% of the business, with BlackRock, Inc., Cadian Capital Management, LP, and The Vanguard Group, Inc. being the largest holders. Insiders own UK£3.7m worth of the company, while the general public holds 27%.
MaxCyte and Lion TCR form Partnership to Support Global Expansion of Lion TCR's TCR-T Cell Pipeline
MaxCyte and Lion TCR have partnered to support the global expansion of Lion TCR's TCR-T cell pipeline, utilizing MaxCyte's Flow Electroporation® technology and ExPERT™ platform. This strategic license grants Lion TCR worldwide non-exclusive clinical and commercial rights to the technology for developing TCR-T cell therapies for solid tumors and viral-related diseases, enhancing MaxCyte's presence in Asia and generating license fees and program-related revenue. The collaboration aims to accelerate personalized cell therapies and off-the-shelf solutions for various cancers and chronic viral diseases.
MaxCyte Confirms Appointment of Maher Masoud as President, Chief Executive Officer and Director
MaxCyte, Inc. has announced the appointment of Maher Masoud as its new President and Chief Executive Officer, effective January 1, 2024. Mr. Masoud will also serve on MaxCyte's Board of Directors. The announcement includes regulatory disclosures regarding his past directorships and current stock options in the company.
CHO cell CRISPR Engineering for enhancing HIV-1 vaccine efficacy
This article discusses the use of CRISPR gene editing in Chinese Hamster Ovary (CHO) cells to enhance the efficacy of HIV-1 vaccines. Researchers engineered CHO cells to lack the MGAT1 enzyme, leading to the production of gp120 protein with desired oligomannose glycans, which improved binding to broadly neutralizing antibodies. This approach offers a promising tool for developing more effective HIV vaccines by addressing limitations of previous vaccine trials like RV144.
CRISPR-Cas9 for large-scale engineering of extracellular nanoparticles
This article discusses NanoMEDIC, a new transient delivery system for CRISPR-Cas9, engineered extracellular nanovesicles that overcome issues of prolonged expression and immunological responses seen with traditional viral vectors. The study successfully scaled up NanoMEDIC production using MaxCyte's cGMP-compatible Flow Electroporation® system, demonstrating its potential for gene therapy and other cargo delivery like vaccine development. This scalable, animal-component-free manufacturing process offers a promising approach for industrial production of CRISPR-Cas9 components.
MaxCyte Signs Strategic Platform License With LG Chem To Advance its Allogeneic CAR-T Programs
MaxCyte, Inc. has entered into a strategic platform license (SPL) agreement with LG Chem Ltd., granting LG Chem non-exclusive rights to MaxCyte’s Flow Electroporation® technology and ExPERT™ platform for clinical and commercial use in their allogeneic CAR-T programs. This partnership, MaxCyte's first SPL with a South Korean company and 17th overall, will provide MaxCyte with platform licensing fees and program-related revenue. LG Chem is advancing its anti-cancer sector through cell drug platform technologies, including LR19023, a next-generation CAR-T cell treatment for solid cancers currently in pre-clinical stages.
MaxCyte Announces Pricing of Upsized Offering and Approval to List on the Nasdaq Global Select Market
MaxCyte, Inc. announced the pricing of an upsized offering of 13,500,000 shares of common stock at US$13.00 per share, aiming to raise approximately US$175.5 million for research, development, manufacturing expansion, and corporate purposes. The company's common stock is set to commence trading on the Nasdaq Global Select Market under the symbol "MXCT" on July 30, 2021, while also maintaining its listing on the AIM market of the London Stock Exchange. The offering is expected to close on August 3, 2021, with Cowen, Stifel, and William Blair acting as joint book-running managers.
MaxCyte® Initiates Launch of New ExPERT™ Range of Expanded Research and GMP Grade Disposables for Complex Cellular Engineering
MaxCyte announced the launch of its new ExPERT™ R-1000 cuvette, the first product in its expanded range of research and GMP grade disposables. The R-1000 can process up to 1 mL or 200 million cells, providing increased versatility for cell therapy drug development and early drug discovery. This new design supports all MaxCyte electroporation instrumentation and aims to accelerate timelines and reduce costs in cellular therapy development.
MaxCyte prepares for "new and exciting" growth chapter - and NASDAQ float - following £25mln fundraiser
MaxCyte PLC's chief executive Doug Doerfler announced a £25.1mln fundraiser, marking the beginning of preparations for a NASDAQ listing and a "new and exciting growth chapter." The funds will support customer scaling, accelerate growth, and explore new product development opportunities. The company aims for a NASDAQ listing within 12-18 months while maintaining its AIM quote.
John W. Holaday, Ph.D.
This article is an in memoriam tribute to John W. Holaday, Ph.D., who passed away on October 4, 2019, at the age of 74. It details his distinguished career as a scientist, entrepreneur, and founder of several life science companies, highlighting his contributions to neuropsychopharmacology, cancer therapeutics, and public health initiatives like DisposeRx. The piece also reflects on his personal qualities and lasting impact on those who knew him.
MaxCyte® Launches ExPERT™ Family of Instruments, Providing a Unifying Technology Platform from Concept to Commercialization for the Next Generation of Cellular Therapies
MaxCyte has launched its new ExPERT™ technology platform, a family of instruments (ATx, STx, and GTx) designed for advanced cellular engineering. This platform aims to provide a unifying technology for developers of cellular therapies, from initial concept through to commercialization. The company states this new generation of instruments will help accelerate timelines, reduce costs, and achieve critical milestones in the development of new cellular therapies.
